dc.contributor.author | Jones, JR | |
dc.contributor.author | Barber, A | |
dc.contributor.author | Le Bihan, Y-V | |
dc.contributor.author | Weinhold, N | |
dc.contributor.author | Ashby, C | |
dc.contributor.author | Walker, BA | |
dc.contributor.author | Wardell, CP | |
dc.contributor.author | Wang, H | |
dc.contributor.author | Kaiser, MF | |
dc.contributor.author | Jackson, GH | |
dc.contributor.author | Davies, FE | |
dc.contributor.author | Chopra, R | |
dc.contributor.author | Morgan, GJ | |
dc.contributor.author | Pawlyn, C | |
dc.date.accessioned | 2021-10-26T08:51:44Z | |
dc.date.available | 2021-10-26T08:51:44Z | |
dc.date.issued | 2021-10-01 | |
dc.identifier.citation | Leukemia, 2021, 35 (10), pp. 3017 - 3020 | |
dc.identifier.issn | 0887-6924 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/4844 | |
dc.identifier.eissn | 1476-5551 | |
dc.identifier.doi | 10.1038/s41375-021-01373-4 | |
dc.format | Print-Electronic | |
dc.format.extent | 3017 - 3020 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | SPRINGERNATURE | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.title | Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2021-07-27 | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.1038/s41375-021-01373-4 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Leukemia | |
pubs.issue | 10 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Hit Discovery & Structural Design | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Myeloma Biology and Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Target Evaluation and Molecular Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Structural Biology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Structural Biology/Hit Discovery & Structural Design | |
pubs.publication-status | Published | |
pubs.volume | 35 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Myeloma Biology and Therapeutics | |
icr.researchteam | Target Evaluation and Molecular Therapeutics | |
icr.researchteam | Hit Discovery & Structural Design | |
dc.contributor.icrauthor | Le Bihan, Yann-Vai | |
dc.contributor.icrauthor | Wang, Hannah | |
dc.contributor.icrauthor | Kaiser, Martin | |
dc.contributor.icrauthor | Pawlyn, Charlotte | |